CYCC

Cyclacel Pharmaceuticals to Release 2014 First Quarter Financial Results

[GlobeNewswire] – BERKELEY HEIGHTS, N.J. — Cyclacel Pharmaceuticals, Inc. (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell … moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click here to view […]

New Japanese Patents Issued Covering Sapacitabine Pharmaceutical Formulations and Combination Treatments

[GlobeNewswire] – BERKELEY HEIGHTS, N.J. — Cyclacel Pharmaceuticals, Inc. (Cyclacel or the Company), today announced that the Japanese Patent and Trademark Office issued two patents broadening the exclusivity of sapacitabine, … moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click here to view […]

Cyclacel Pharmaceuticals’ CEO Discusses Q4 2013 Results – Earnings Call Transcript

[at Seeking Alpha] – Spiro Rombotis Thank you, Bill and good afternoon. During 2013, we continued to progress clinical development of sapacitabine in patients with acute myeloid leukemia or AML and myelodysplastic syndromes … moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click here to view […]

Combination Potential of Cyclacel’s Sapacitabine and Seliciclib Reported at AACR

[at noodls] – Sequential Treatment Showed Antitumor Activity in Patients With Incurable BRCA-Deficient Cancers BERKELEY HEIGHTS, N.J., April 9, 2013 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) … moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click here to view […]

AACR Press Conference Highlights Combination Potential of Two Cyclacel Drugs

[at noodls] – Novel Drug Combination Active in Patients With Incurable BRCA-Deficient Cancers WASHINGTON, April 8, 2013 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel … moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click here to view […]

Cyclacel Announces Sale of Four Cyclacel Romidepsin-Related Patents to Celgene and Dismissal of All Claims in Their Patent Litigation

[at noodls] – BERKELEY HEIGHTS, N.J., April 4, 2013 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) announced that it has entered into … moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click here to view […]

Cyclacel Announces Multiple Abstracts Selected for Presentation at American Association for Cancer Research Annual Meeting

[at noodls] – BERKELEY HEIGHTS, N.J., April 3, 2013 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that … moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click here to view […]